Citi Comments on Amylin Pharmaceuticals Drugs Results

Citi is commenting on drug results from Amylin Pharmaceuticals, Inc. AMLN. “GLP-1 TRx and NRx scrips (Byetta + Victoza) are up 1.6% and down 0.3% wk/wk, respectively,” Citi writes. “Overall the GLP-1 market has grown nicely since Victoza's launch as indicated by the 4 wk average (TRx +34.7%, NRx +42.4%). This shows physicians prefer convenient and efficacious therapies in our view. “Our analysis of weekly IMS scrips suggests that Byetta is tracking at $125M vs.Citi Q1 ests of $129M. IMS scrip data indicates that Byetta TRx is tracking down 1.8% q/q. This is based on 8 of the total 14 weeks for Q1.” Amylin Pharmaceuticals closed Friday at $13.45.